Overview of first-salvage regimens containing BV or CPI
| Study . | N . | Intervention . | Schedule . | Refractory, n (%) . | CMR pre-ASCT, n (%) . | 2-year PFS . | 2-year OS . |
|---|---|---|---|---|---|---|---|
| Moskowitz et al (2017)4 | 65 | BV + sequential ICE | BV 1.2 mg/kg d1, 8, 15 of 28-d cycles, 2 cycles. ICE salvage in case of Deauville >3. | 34 (52) | 54 (83) | 82% | 97% |
| Herrera et al (2018)5 | 57 | BV + sequential ICE/GVD | BV 1.8 mg/kg every 21 d, 4 cycles. Last 2 cycles BV escalation to 2.4 mg/kg in n = 8 patients with PR/SD. Salvage chemotherapy at discretion of treating physician. | 35 (61) | 37 (65) | 67% | 93% |
| Cole et al (2018)6 | 45 | BV + gemcitabine | BV 1.8 mg/kg on d1 and d8 every 21 days, 4 cycles. In combination with gemcitabine. | 29 (64) | 28 (67) | — | 1 year: 95% |
| LaCasce et al (2018)9 | 55 | BV + bendamustine | BV 1.8 mg/kg every 21 d, 2-6 cycles. In combination with bendamustine. Post-ASCT BV monotherapy maintenance up to 16 cycles. | 28 (51) | 39 (74) | 63% | 94% |
| Garcia-Sanz et al (2019)8 | 66 | BV + ESHAP | BV 1.8 mg/kg every 21 days, 4 cycles. In combination with 3 cycles of ESHAP. | 40 (61) | 46 (70) | 71% | 90% |
| Broccoli et al (2019)7 | 40 | BV + bendamustine | BV 1.8 mg/kg every 21 days, 4-6 cycles. In combination with bendamustine. | 20 (50) | 30 (79) | 68% | 97% |
| Abuelgasim et al (2019)19 | 28 | BV + IGEV | BV 1.8 mg/kg every 21 days, 2-4 cycles. In combination with IGEV. 64% received BV consolidation after ASCT. | 12 (43) including n = 14 with >1 line of therapy. | 70% | 73.5% (100% for patients with first relapse) | 87.1% (100% for patients with first relapse) |
| Kersten et al (2021)3 | 67 | BV + DHAP | BV 1.8 mg/kg every 21 days, 3 cycles. In combination with DHAP. | 30 (45) | 53 (82) | 78% | 96% |
| Advani et al (2021)10 | 91 | BV + nivolumab | BV 1.8 mg/kg and nivolumab 3.0 mg/kg every 21 days, 4 cycles. | 38 (42) | 61 (67) | 78% | 93% |
| Moskowitz et al (2021)20 | 39 | Pembrolizumab + GVD | Pembrolizumab 200 mg every 21 days, 4 cycles. In combination with GVD. | 16 (41) | 36 (95) | 1 year: 100% | 1 year: 100% |
| Study . | N . | Intervention . | Schedule . | Refractory, n (%) . | CMR pre-ASCT, n (%) . | 2-year PFS . | 2-year OS . |
|---|---|---|---|---|---|---|---|
| Moskowitz et al (2017)4 | 65 | BV + sequential ICE | BV 1.2 mg/kg d1, 8, 15 of 28-d cycles, 2 cycles. ICE salvage in case of Deauville >3. | 34 (52) | 54 (83) | 82% | 97% |
| Herrera et al (2018)5 | 57 | BV + sequential ICE/GVD | BV 1.8 mg/kg every 21 d, 4 cycles. Last 2 cycles BV escalation to 2.4 mg/kg in n = 8 patients with PR/SD. Salvage chemotherapy at discretion of treating physician. | 35 (61) | 37 (65) | 67% | 93% |
| Cole et al (2018)6 | 45 | BV + gemcitabine | BV 1.8 mg/kg on d1 and d8 every 21 days, 4 cycles. In combination with gemcitabine. | 29 (64) | 28 (67) | — | 1 year: 95% |
| LaCasce et al (2018)9 | 55 | BV + bendamustine | BV 1.8 mg/kg every 21 d, 2-6 cycles. In combination with bendamustine. Post-ASCT BV monotherapy maintenance up to 16 cycles. | 28 (51) | 39 (74) | 63% | 94% |
| Garcia-Sanz et al (2019)8 | 66 | BV + ESHAP | BV 1.8 mg/kg every 21 days, 4 cycles. In combination with 3 cycles of ESHAP. | 40 (61) | 46 (70) | 71% | 90% |
| Broccoli et al (2019)7 | 40 | BV + bendamustine | BV 1.8 mg/kg every 21 days, 4-6 cycles. In combination with bendamustine. | 20 (50) | 30 (79) | 68% | 97% |
| Abuelgasim et al (2019)19 | 28 | BV + IGEV | BV 1.8 mg/kg every 21 days, 2-4 cycles. In combination with IGEV. 64% received BV consolidation after ASCT. | 12 (43) including n = 14 with >1 line of therapy. | 70% | 73.5% (100% for patients with first relapse) | 87.1% (100% for patients with first relapse) |
| Kersten et al (2021)3 | 67 | BV + DHAP | BV 1.8 mg/kg every 21 days, 3 cycles. In combination with DHAP. | 30 (45) | 53 (82) | 78% | 96% |
| Advani et al (2021)10 | 91 | BV + nivolumab | BV 1.8 mg/kg and nivolumab 3.0 mg/kg every 21 days, 4 cycles. | 38 (42) | 61 (67) | 78% | 93% |
| Moskowitz et al (2021)20 | 39 | Pembrolizumab + GVD | Pembrolizumab 200 mg every 21 days, 4 cycles. In combination with GVD. | 16 (41) | 36 (95) | 1 year: 100% | 1 year: 100% |
d, day; IGEV, ifosfamide, gemcitabine, vinorelbine, and prednisolone; SD, stable disease.